Patents by Inventor Michael Pollastri

Michael Pollastri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
    Patent number: 10314810
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: June 11, 2019
    Assignees: Trustees of Boston University, Northeastern University, Boston Medical Center Corporation
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
    Patent number: 10258600
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 16, 2019
    Assignees: Trustees of Boston University, Boston Medical Center, Northeastern University
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS
    Publication number: 20160175278
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Application
    Filed: March 3, 2016
    Publication date: June 23, 2016
    Applicants: Trustees of Boston University, Northeastern University, Boston Medical Center Corporation
    Inventors: David H. SHERR, Michael POLLASTRI, Jennifer SCHLEZINGER, Sarah HAIGH MOLINA, Scott SCHAUS, Joshua Robert GIGUERE
  • ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS
    Publication number: 20130281525
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Application
    Filed: July 27, 2011
    Publication date: October 24, 2013
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION, NORTHEASTERN UNIVERSITY
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • Quinoline and quinoxaline compounds
    Publication number: 20060122224
    Abstract: Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Application
    Filed: December 15, 2005
    Publication date: June 8, 2006
    Inventors: Bruce Bechle, George Chang, Mary Diduik, Jari Finneman, Ravi Garigipati, Rayn Kelley, David Perry, Michael Pollastri, Roger Ruggeri